Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus.

MedStar author(s):
Citation: Diabetes Care. 37(4):909-11, 2014 Apr.PMID: 24271189Institution: MedStar Washington Hospital CenterDepartment: Medicine/EndocrinologyForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, N.I.H., ExtramuralSubject headings: *Diabetes Mellitus, Type 2/ep [Epidemiology] | *Diabetes Mellitus, Type 2/ge [Genetics] | *Diabetes, Gestational/dt [Drug Therapy] | *Diabetes, Gestational/ep [Epidemiology] | *Hypoglycemic Agents/tu [Therapeutic Use] | *Life Style | *Metformin/tu [Therapeutic Use] | *Prediabetic State/dt [Drug Therapy] | *Prediabetic State/ep [Epidemiology] | Adult | Case-Control Studies | Disease Progression | Female | Humans | Islets of Langerhans/pp [Physiopathology] | Pregnancy | Risk FactorsYear: 2014Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006ISSN:
  • 0149-5992
Name of journal: Diabetes careAbstract: OBJECTIVE The Diabetes Prevention Program (DPP) trial investigated rates of progression to diabetes among adults with prediabetes randomized to treatment with placebo, metformin, or intensive lifestyle intervention. Among women in the DPP, diabetes risk reduction with metformin was greater in women with prior gestational diabetes mellitus (GDM) compared with women without GDM but with one or more previous live births. RESEARCH DESIGN AND METHODS We asked if genetic variability could account for these differences by comparing beta-cell function and genetic risk scores (GRS), calculated from 34 diabetes-associated loci, between women with and without histories of GDM. RESULTS beta-Cell function was reduced in women with GDM. The GRS was positively associated with a history of GDM; however, the GRS did not predict progression to diabetes or modulate response to intervention. CONCLUSIONS These data suggest that a diabetes-associated GRS is associated with development of GDM and may characterize women at risk for development of diabetes due to beta-cell dysfunction.All authors: Christophi CA, Dabelea D, Dagogo-Jack S, Diabetes Prevention Program Research Group, Florez JC, Franks PW, Jablonski KA, Kim C, Knowler WC, Ratner R, Sullivan SDFiscal year: FY2014Digital Object Identifier: Date added to catalog: 2015-03-17
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 24271189 Available 24271189

Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006

OBJECTIVE The Diabetes Prevention Program (DPP) trial investigated rates of progression to diabetes among adults with prediabetes randomized to treatment with placebo, metformin, or intensive lifestyle intervention. Among women in the DPP, diabetes risk reduction with metformin was greater in women with prior gestational diabetes mellitus (GDM) compared with women without GDM but with one or more previous live births. RESEARCH DESIGN AND METHODS We asked if genetic variability could account for these differences by comparing beta-cell function and genetic risk scores (GRS), calculated from 34 diabetes-associated loci, between women with and without histories of GDM. RESULTS beta-Cell function was reduced in women with GDM. The GRS was positively associated with a history of GDM; however, the GRS did not predict progression to diabetes or modulate response to intervention. CONCLUSIONS These data suggest that a diabetes-associated GRS is associated with development of GDM and may characterize women at risk for development of diabetes due to beta-cell dysfunction.

English

Powered by Koha